Research programme: diamorphine analogue vaccine - Opiant Pharmaceuticals

Drug Profile

Research programme: diamorphine analogue vaccine - Opiant Pharmaceuticals

Alternative Names: Adjuvanted heroin analogue vaccine - Opiant; Heroin vaccine - Opiant; OPNT 005

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute on Drug Abuse; Walter Reed Army Institute of Research
  • Developer National Institute on Drug Abuse; Opiant Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Drug withdrawal therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heroin abuse

Most Recent Events

  • 18 Dec 2017 Pharmacodynamics and immunogenicity data from preclinical trials in Heroin abuse released by Opiant Pharmaceuticals
  • 18 Dec 2017 Opiant Pharmaceuticals plans clinical trials for Heroin abuse
  • 28 Oct 2016 Preclinical trials in Heroin abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top